Drug Pipeline

Alendronate Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
1
Recruiting
5
Top Sponsors
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-05 NCT06973109
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
overall status: "Not Yet Recruiting" → "Withdrawn"
2026-06-05 NCT06973109
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
critical why stopped: null → "Investigator left the institution"
2026-06-05 NCT06973109
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
Enrollment reduced: 36 -> 0 participants
2026-06-05 NCT06973109
Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes
Sponsor changed: Nitin Agarwal -> University of Pittsburgh
Active Studies by Phase
Phase 4
2
Phase 2
3
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT06264609 Precision Medicine Approach for Osteoporosis - Follow Up Study Osteoporosis Enrolling by Invitation
NCT05151484 Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover Age-Related Osteoporosis Active, Not Recruiting
Phase 2
NCT06016634 Alendronate for Osteonecrosis in Adults With Sickle Cell Disease Sickle Cell Disease Recruiting
NCT07471880 A Phase II Trial of RAB001 (LLP2A-Alendronate) for Steroid-Induced Early-Stage… Osteonecrosis Active, Not Recruiting
NCT07216794 Small Trial of Alendronate Impact on the Reservoir of HIV HIV Not Yet Recruiting
Sponsors Running Alendronate Trials
Disease Areas
Get alerts when Alendronate trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free